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BACKGROUND: Tumour stromal cells differ from its normal counterpart. We have shown that tumour endothelial cells (TECs) isolated
from tumour tissues are also abnormal. Furthermore, we found that mRNAs of vascular endothelial growth factor-A (VEGF-A) and
cyclooxygenase-2 (COX-2) were upregulated in TECs. Vascular endothelial growth factor-A and COX-2 are angiogenic factors and
their mRNAs contain an AU-rich element (ARE). AU-rich element-containing mRNAs are reportedly stabilised by Hu antigen
R (HuR), which is exported to the cytoplasm.
METHODS: Normal endothelial cell (NEC) and two types of TECs were isolated. We evaluated the correlation of HuR and
accumulation of VEGF-A and COX-2 mRNAs in TECs and effects of HuR on biological phenotypes of TECs.
RESULTS: The HuR protein was accumulated in the cytoplasm of TECs, but not in NECs. Vascular endothelial growth factor-A and
COX-2 mRNA levels decreased due to HuR knockdown and it was shown that these ARE-mRNA were bound to HuR in TECs.
Furthermore, HuR knockdown inhibited cell survival, random motility, tube formation, and Akt phosphorylation in TECs.
CONCLUSION: Hu antigen R is associated with the upregulation of VEGF-A and COX-2 mRNA in TECs, and has an important role in
keeping an angiogenic switch on, through activating angiogenic phenotype in tumour endothelium.
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Tumour stroma includes various types of cells, such as leukocytes,
lymphocytes, macrophages, fibroblasts, and endothelial cells
(ECs). Tumour stromal cells are different from their normal
counterparts. For example, cancer-associated fibroblasts promote
cancer progression (Kalluri and Zeisberg, 2006) and tumour-
associated macrophages produce epithelial growth factor, which
stimulate tumour cell migration in breast cancer (Wyckoff et al,
2004). We previously found that tumour endothelial cells (TECs),
which are also components of the tumour stroma, are different
from normal endothelial cells (NECs) (Hida et al, 2004; Hida and
Klagsbrun, 2005; Ohga et al, 2009). For example, TECs are
cytogenetically abnormal (Hida et al, 2004; Akino et al, 2009), and
they express specific markers such as tumour endothelial markers
(TEMs) and upregulate growth factor receptor, such as vascular
endothelial growth factor receptor (VEGFR) or epithelial growth
factor receptor (Hida et al, 2008). Also, TECs show higher
proliferation and resistance to serum starvation (Matsuda et al,
2010). Furthermore, they upregulate mRNA of VEGF-A and
cyclooxygenase (COX)-2, which are generally expressed in tumour
and other stromal cells. This suggests the presence of a functional
autocrine pathway related to VEGF-A or COX-2 in mouse TECs.
Vascular endothelial growth factor is released by various normal
and transformed cells under certain conditions such as hypoxia or
growth factor stimulation, but particularly under the tumour
microenvironment. Vascular endothelial growth factor-A is the
most potent inducer of EC proliferation, migration, and survival
(Ferrara and Davis-Smyth, 1997). Both tumour and stromal VEGF
contribute to tumour angiogenesis.
Cyclooxygenase is a rate-limiting enzyme in the prostaglandin
(PG) biosynthetic pathway. Cyclooxygenase consists of the
following two isoforms: COX-1, which is expressed constitutively
in most cells and COX-2, which is inducible by mitogens and
proinflammatory cytokines during pathological processes, includ-
ing inflammation (Hla et al, 1993). Cyclooxygenase-2 is also
induced by growth factors, including VEGF (Hernandez et al, 2001;
Tamura et al, 2002) and basic fibroblast growth factor (Kage et al,
1999). Thus, COX-2 is an important mediator of angiogenesis and
tumour growth (Gately and Li, 2004).
Recent studies have shown that PGE2 (a downstream product of
COX-2 metabolism) stimulates VEGF expression in ECs (Pai et al,
2001), and COX-2 induced by VEGF also has an important role in
tumour angiogenesis (Wu et al, 2006). Thus, VEGF and COX-2-
dependent PGE2 are important for angiogenesis (Tamura et al,
2006).
The mRNAs transcribed from VEGF-A and COX-2 genes include
an AU-rich element (ARE). Several proto-oncogenes, such as
c-myc or c-fos, possess an ARE in the 30-untranslated regions of
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stheir mRNA. These mRNAs are stabilised by Hu antigen R (HuR)
protein (Lopez de Silanes et al, 2005), a ubiquitously expressing
protein belonging to the ELAV-like family of RNA-binding
proteins, which regulates the expression of labile ARE-mRNAs
by enhancing their stability and translation (Brennan and Steitz,
2001). Hu antigen R is predominantly localised in the nucleus of
most unstimulated cells; however, it can also translocate to the
cytoplasm with the target mRNAs and prevent their decay
under stress such as heat shock (Gallouzi et al, 2001) and hypoxia
(Levy et al, 1998). Although the precise transport mechanism
remains unknown, it differs in tumour cells compared with that in
normal cells (Higashino et al, 2005; Hasegawa et al, 2009).
Cytoplasmic HuR expression has been implicated in the malig-
nancy of several tumours (Lopez de Silanes et al, 2003, 2005;
Denkert et al, 2004; Erkinheimo et al, 2005; Heinonen et al, 2005;
Cho et al, 2007a,b; Niesporek et al, 2008; Hasegawa et al, 2009).
However, there are no reports about the function of HuR in
vascular ECs.
In this study, we evaluated the correlation of HuR and
accumulation of VEGF-A and COX-2 mRNAs in TECs.
Furthermore, we analysed how HuR affects biological phenotypes
of TECs.
MATERIALS AND METHODS
Cell lines and culture conditions
Cells from super-metastatic human malignant melanoma cell line
A375SM, kindly donated by Dr IJ Fidler (MD Anderson Cancer
Center, Houston, TX, USA) were cultured in a humidified
atmosphere of 5% CO2 and 95% air at 371C in minimum essential
medium (Gibco, Grand Island, NY, USA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS). The human oral
carcinoma cell line HSC-3 was supplied by the Japanese Cancer
Research Bank (Tokyo, Japan). The cells were cultured in
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, St Louis,
MO, USA) supplemented with 10% FBS. Human dermal micro-
vascular endothelial cells (HMVECs) were purchased (Lonza,
Walkersville, MD, USA) and cultured in endothelial growth
medium (EGM-2 MV; Lonza) and 5% FBS.
Antibodies
The antibodies purchased were rat anti-mouse CD31 and
fluorescein isothiocyanate (FITC)-anti-mouse CD31 (eBioscience,
San Diego, CA, USA), FITC-Bandeirea simplicifolia lectin 1-B4
(BS1-B4; Vector Laboratories, Burlingame, CA, USA), FITC-
anti-rat IgG, anti-HuR (3A2) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); PE-anti-human CD31 (eBioscience); FITC-anti-
rabbit IgG (eBioscience); rabbit polyclonal to VEGF-A (Abcam,
Cambridge, MA, USA); COX-2 (Cell Signaling, Beverly, MA, USA);
anti-monoclonalb-actin-peroxidase (Sigma-Aldrich); anti-hnRNP
A1(E-17):SC10030 (Santa Cruz) (Santa Cruz Biotechnology),
anti-b-tubulin (Millipore, Bivellica, MA, USA) p-Akt (Cell
Signaling Technology), Akt (Cell Signaling Technology);
HRP-conjugated goat anti-rabbit IgG antibody (Cell Signaling),
HRP-conjugated goat anti-mouse IgG antibody (Jackson Immuno-
Research), HRP-conjugated mouse anti-goat antibody (Jackson
ImmunoResearch).
Isolation of TECs and NECs
All animal procedures were performed in compliance with the
guidelines prescribed by Hokkaido University, and protocols were
approved by the Institutional Animal Care and Use Committee.
Endothelial cells were isolated as described previously (Hida et al,
2004). Briefly, TECs were isolated from melanoma (A375SM) and
oral carcinoma (HSC-3) xenografts of nude mice aged 8–12 weeks
(Sankyo Labo Service Corporation, Inc., Tokyo, Japan). Normal
endothelial cells were isolated from the dermal tissue and used as
controls. Endothelial cells were isolated with a magnetic cell
sorting system (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions, using the FITC-anti-
CD31 antibody. CD31-positive cells were sorted and plated onto
1.5% gelatin-coated culture plates and grown in EGM-2 MV with
5% FBS. Diphtheria toxin (Calbiochem, San Diego, CA, USA)
(500ngml
–1) was added to TEC subcultures to kill any remaining
human tumour cells (Arbiser et al, 1999), and to NECs to ensure
technical consistency. The isolated ECs were purified by a second
round of purification using FITC-BS1-B4, and purity was
determined using flow cytometry (Hida et al, 2004). Tumour
endothelial cells and NECs were characterised as described
previously (Akino et al, 2009; Ohga et al, 2009; Matsuda et al,
2010). Tumour endothelial cells are positive for EC markers
(VEGFR-1, VEGFR-2, CD31, CD144) and negative for haemato-
poietic markers (CD11b, CD45) (Supplementary Figure S1). All
ECs were used between 15 and 20 passages.
HuR knockdown
Hu antigen R siRNA was transfected using HiPerFect transfection
reagent (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The HuR mRNA and protein knockdown level
was analysed using qRT–PCR and western blot analysis. The HuR
siRNA was 50-UUACCAGUUUCAAAUGGUCATT-30 (Hasegawa
et al, 2009; Kakuguchi et al, 2010), and the control siRNA was
AllStars negative control siRNA (Qiagen).
Cell fractionation
Cell fractionation was performed by separating cells into
cytoplasmic and nuclear fractions, as described previously (Weigel
and Dobbelstein, 2000). The cells were harvested and resuspended
in a fractionating buffer (10mM Tris–HCl, pH 7.6; 150mM NaCl;
1.5mM MgCl2, 0.5% Nonidet P-40 (Sigma-Aldrich), and protease
inhibitor cocktail), followed by vigorous shaking for 5min and
centrifuged at 12000r.p.m. for 30s. The supernatant was used
as the cytoplasmic fraction. The accuracy of cell fractionation
was confirmed by immunoblotting using cytoplasmic protein;
b-tubulin and nuclear protein; hnRNP.
Quantitative real-time RT–PCR
Total RNA was isolated from ECs using the RNeasy Micro kit
(Qiagen) using the RNase-free DNase Set (Qiagen). RNA was
quantified using spectrophotometry. Total RNA was then used for
performing first-strand complementary DNA synthesis by using
the ReverTra-Plus (Toyobo, Osaka, Japan). Real-time PCR was
conducted using the SYBR Green Realtime PCR Master Mix Plus
(Toyobo). Cycling conditions were set according to the manu-
facturer’s instructions based on the use of Opticon Monitor
version 3.0 (Bio-Rad, Hercules, CA, USA).
To evaluate the half-life of VEGF-A and COX-2 mRNA, oral
carcinoma EC and melanoma EC and skin EC were treated with
actinomycin D (Act. D) (Sigma-Aldrich) (5mgml
–1) for the
indicated time periods. The extracted RNA was subjected to
quantitative real-time RT–PCR. The VEGF-A and COX-2 mRNA
expression levels in ECs were normalised to GAPDH levels. The
experiment was performed three times and similar results were
obtained. The primers used were as follows: GAPDH, forward
50-TCTGACGTGCCGCCTGGAG-30, reverse 50-TCGCAGGAGACAA
CCTGGTC-30; VEGF-A, forward 50- GATTGAGACCCTGGTGGACA
TC-30, reverse 50- CACACAGGAGGGCTTGAAGA-30; COX-2,f o r w a r d
50- CAGACAACATAAACTGCGCCTTTT-30, reverse 50- GACTTCC
TGCCCCACAGCAA-30; HuR, forward 50-CCTCCGAGCCCATC
ACAGT-30, reverse 50-GCGAGAGGAGAGCCATGTTT-30.
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Ribonucleoprotein (RNP) immunoprecipitation assay was performed
as described previously (Higashino et al, 2005). Tumour endothelial
cells were treated with PBS containing 1% formaldehyde and the
lysate was immunoprecipitated with mouse IgG (eBioscience) or
anti-HuR antibody (Santa Cruz). The pellets were incubated at 701C
for 45min to reverse the cross-links, the isolated RNA was subjected
to reverse transcription, and PCR amplification for VEGF-A, COX-2
was performed using the primers as described above.
Immunocytochemistry and immunohistochemistry
Human tissue samples were obtained from excised renal cell
carcinoma and normal renal tissue of four patients at Hokkaido
University Hospital, Hokkaido, Japan, and from normal renal
tissues. Informed consent was obtained from all patients before the
samples were used.
Frozen sections were fixed in cold acetone for 15min and
blocked with 2% goat and 5% sheep serum in PBS for 1h at room
temperature. Serial sections were incubated with primary anti-
bodies (CD31, HuR) for 16h.
Immunohistochemical detections of CD31 and HuR in serial
sections were carried out using the avidin–biotin complex method
as previously described (Shindoh et al, 1996).
Furthermore, the cryosections of renal carcinoma and normal
renal tissue were double stained using PE-anti-human CD31
antibody and anti-human HuR antibody, Alexa488-conjugated
anti-mouse IgG antibody to show co-localisation of HuR in EC.
Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI). In
addition, cultured ECs were fixed in methanol and stained with
anti-HuR antibody and then with FITC-conjugated secondary
antibody. All samples in immunocytochemistry were counter-
stained with DAPI (Roche, Indianapolis, IN, USA). The cells were
observed using an OLYMPUS IX71 fluorescence microscope
(Olympus, Tokyo, Japan).
Western blot analysis
Western blot analysis was performed using antibodies specific to HuR,
V E G F - A ,C O X - 2 ,p - A k t ,A k t ,b-actin, and HRP-conjugated secondary
antibody as described previously (Hasegawa et al, 2009; Ohga et al,
2009). The accuracy of cell fractionation was confirmed by immuno-
blotting using cytoplasmic protein; b-tubulin and nuclear protein;
hnRNP (Hasegawa et al, 2009). The levels of VEGF-A and COX-2 were
normalised to b-actin and analysed by scanning densitometry using
Image J software from the NIH (Bethesda, MD, USA).
Cell proliferation (survival) assay
Tumour endothelial cells were treated with control siRNA (5nM),
HuR siRNA (5nM), and without siRNA. After siRNA transfection for
24h, 5 10
4 cells per well were seeded into 12-well dishes in EBM-2
with 0.5% FBS (low serum medium), and then VEGF (10ngml
–1)o r
PGE2 (10nM) was added. Tumour endothelial cells were trypsinised
and the cell number was counted 48h after cell seeding. The
experiment was performed three times and similar results were
obtained. Statistical analysis was performed using the Mann–
Whitney U-test. A P-value of o0.05 was considered significant.
Cell migration assay
Random motility of TECs was measured by a migration assay
using a Boyden chamber as described previously (Dormond et al,
2001). Tumour endothelial cells were treated with control siRNA
(5nM), HuR siRNA (5nM), or without siRNA in low serum medium
for 48h. In all, 1.5 10
4 cells were seeded in the upper chambers in
low serum medium, and then VEGF (10ngml
–1) or PGE2 (10nM)
was added. No chemoattractant was added to the lower chambers.
Tube formation assay
Diluted Matrigel (BD Biosciences, San Jose, CA, USA) was
transferred to each well of a 24-well dish and incubated at 371C
for 30min to allow the matrix solution to solidify. Tumour
endothelial cells were harvested and resuspended in appropriate
media and then seeded at a density of 1 10
5 cells per well,
followed by incubation at 371C for 12h. Tube formation was
observed using an inverted microscope and the experimental
results were recorded at different times. The number of tube
junctions/areas was counted.
RESULTS
VEGF-A and COX-2 were upregulated in TECs not in NECs
Vascular endothelial growth factor-A and COX-2 are upregulated
in tumour cells; however, only a few studies report about
their expression in TECs (Masferrer et al, 2000; Leahy et al,
2002). We previously isolated TECs from four kinds of tumour
xenografts in nude mice, and observed that TECs as well as NECs
expressed typical EC markers such as CD31, CD105, and CD144.
Using these isolated ECs, we reported that TECs are different from
NECs (Hida et al, 2004, 2008; Hida and Klagsbrun, 2005). For
example, TECs are more proliferative and migratory than NECs.
In addition, gene expression pattern in TECs is different from that
in NECs. Our recent microarray analysis showed that several genes
in TECs, such as VEGFR-2 and reported TEC markers, including
TEM-8 (St Croix et al, 2000), CD13 (Pasqualini et al, 2000), and
Dkk-3 (Untergasser et al, 2008; Fong et al, 2009), were expressed
excessively. Of these, we have chosen VEGF-A and COX-2 mRNAs
to examine their expression in TECs. The levels of VEGF-A and
COX-2 mRNAs in TECs were several folds higher than those
in NECs, based on the results from regular RT–PCR (Figure 1A)
and real-time PCR (Figure 1B) analyses. We also found that
VEGFR-1 or -2 mRNAs were upregulated in TECs (data not
shown). In addition, western blotting of VEGF-A and COX-2 also
showed that VEGF-A and COX-2 proteins expression were
upregulated in TECs (Figures 1C and D).
These findings suggested that VEGF-A and COX-2 expression
have an important role in the increased proliferative rate of TECs.
Differential localisation of HuR between TECs and NECs
in vitro and in vivo
Since VEGF-A and COX-2 mRNAs are ARE-mRNAs, we next
focused on HuR. Hu antigen R is only localised in the nucleus of
normal cells, but it is localised also in the cytoplasm of cells under
stress – such as heat shock or hypoxia – or in the cytoplasm of
malignant cells (Levy et al, 1998; Gallouzi et al, 2001).
Consistent with the results in the previous reports about HuR
localisation in normal and malignant cells, HuR was expressed
only in the nucleus of HMVECs; however, it was also expressed in
the cytoplasm and nucleus of malignant melanoma and oral
carcinoma cells (Figure 2A). To examine the HuR localisation in
TECs and NECs, we isolated mouse ECs (Figure 2B). Hu antigen R
expression was detected only in the nucleus of NECs with anti-HuR
antibody, similar to that in HMVECs. In contrast, both the
cytoplasm and nucleus of TEC, which were isolated from oral
carcinoma and melanoma ECs, were stained positively with anti-
HuR antibody (Santa Cruz Biotechnology).
To confirm the cytoplasmic localisation of HuR in TEC, ECs
were separated into the cytoplasmic and nuclear fractions. Using
two antibodies, anti-hnRNP (nuclear protein) and anti-b-tubulin
(cytoplasmic protein), we could confirm that nuclear and
cytoplasmic protein extracts were pure in each fraction.
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amounts of HuR in the cytoplasm of TECs were much higher than
that in NECs (Figures 2C and D). These results also suggest that
HuR is accumulated in the TEC cytoplasm, similar to the
malignant melanoma cells.
We next examined HuR localisation in a human tumour or
normal blood vessels by immunohistochemistry using serial frozen
sections of human tumours and normal kidney tissues. In normal
blood vessels, which were stained by anti-CD31 (BD Biosciences),
HuR expression was localised only in the nuclei of ECs (black arrow,
Figure 2E). On the other hand, HuR expression was detected not only
in the nuclei and cytoplasm of TECs, which were stained with CD31
(yellow arrow, Figure 2E). Furthermore, in immunofluorescent
double staining with anti-CD31 and anti-HuR antibodies in same
frozen sections of human renal tumours and normal renal tissues,
HuR is stained in cytoplasm in TECs stained with anti-CD31, but
only in nuclei in NEC, consistently with Figures 2E and F. These
results suggested that HuR was expressed in the cytoplasm of both
mouse TECs and human TECs, similar to malignant cells.
HuR knockdown reduces VEGF-A and COX-2 expression
in TECs
To explore the role of HuR in the expression of VEGF-A and COX-
2 mRNA of TECs, TECs were subjected to RNAi using HuR siRNA
to silence HuR expression (Hasegawa et al, 2009; Kakuguchi et al,
2010). Hu antigen R knockdown both in oral carcinoma and
melanoma ECs was confirmed in its mRNA level (Figures 3A
and B) and in its protein level. The expression of VEGF-A and
COX-2 protein were also downregulated in HuR-knockdown TECs
(Figures 3C and D).
The quantity of VEGF-A and COX-2 mRNA in the cytoplasm of
HuR-knockdown cells was reduced to almost half of the amount of
TECs in which control siRNA (Qiagen GmbH) was introduced
(Figure 4A), suggesting that HuR contributes to the export of
VEGF-A and COX-2 mRNAs in TECs. The accumulation of VEGF-
A and COX-2 mRNA in both cells was also downregulated in HuR-
knockdown cells (Figure 4B). Furthermore, the half-lives of VEGF-
A and COX-2 mRNA were shortened by HuR knockdown
(Figure 4C). It was expected that these mRNA stability was greater
in TEC compared with NEC, since cytoplasmic HuR expression of
TEC was higher than that of NEC. It was shown that the half-life of
VEGF-A mRNA was longer in TEC compared with NEC as
expected (Figure 4C). To address whether HuR indeed associates
VEGF-A or COX-2 mRNA directly, we performed a RIP assay.
Since the bands of VEGF-A and COX-2 mRNAs were visible in the
samples co-precipitated with HuR (Figure 4D), the data indicate
that HuR binds to these mRNAs. These results suggest that HuR
contributes to the stabilisation of VEGF-A and COX-2 mRNAs by
binding to these mRNAs.
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Figure 1 VEGF-A and COX-2 were upregulated in TECs. COX-2 and VEGF-A mRNA levels in regular RT–PCR (A). Relative expression of VEGF-A and
COX-2 mRNAs in TECs (oral carcinoma and melanoma ECs) and NEC (skin EC) was measured using quantitative real-time RT–PCR (B). VEGF-A
and COX-2 mRNA levels were significantly higher in TECs than in NECs (*Po0.05 vs skin EC). Western blotting of VEGF-A and COX-2 also showed that
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Vascular endothelial growth factor-A and COX-2 are proangio-
genic factors and affect biological cellular phenotypes such as
proliferation, migration, and survival (Ferrara and Davis-Smyth,
1997; Williams et al, 1999).
To analyse the effects of VEGF-A and COX-2 downregulation
mediated by HuR knockdown in TECs, we performed a cell
proliferation assay under a low serum condition. Hu antigen R
knockdown produced starved oral carcinoma and melanoma ECs
compared with TECs, which were untreated or transfected with
control siRNA (Figure 5A). Interestingly, when treated with VEGF
(10ngml
–1; Lonza) or PGE2 (10nM; Cayman Chemical, Ann Arbor,
MI, USA), cell proliferation of both TECs, even those transfected
with siHuR, were restored. These results suggest that VEGF and
PGE2-treated TECs survive under serum starvation, and HuR
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VEGF-A and COX-2 mRNAs.
HuR knockdown inhibits random motility and Akt
phosphorylation in TECs
To analyse another effect of HuR knockdown on angiogenic
properties of TECs, we performed a cell migration assay using a
Boyden chamber (Neuro Probe Inc., Gaithersburg, MD, USA)
(Figure 5B). No chemoattractant was added to the upper and lower
chambers, which enabled us to assess the random motility of TECs.
The migrating cell number decreased significantly by HuR
knockdown both in oral carcinoma and melanoma ECs. When
VEGF (10ngml
–1) or PGE2 (10nM) was added to the upper
chamber, the number of cells that migrated towards the lower
chamber was restored.
During angiogenesis, VEGF signalling is mediated by ligand-
dependent signalling through the PI3K/Akt pathway (Rodriguez
et al, 2006). The protein kinase Akt has a central role in mature
ECs. Activation of Akt promotes cell survival by inhibiting
apoptosis (Gerber et al, 1998) and mediates VEGF-induced
migration (Dimmeler et al, 2000; Morales-Ruiz et al, 2000).
Cyclooxygenase-2-overexpressed cells produce PGs that stimulate
both EC migration and tube formation (Tsujii et al, 1998). Hence,
we analysed the effect of HuR knockdown on Akt phosphorylation
in TECs (Figure 5C). Hu antigen R knockdown inhibited Akt
phosphorylation in both TECs, whereas treatment with VEGF and
PGE2 for 30min recovered Akt phosphorylation. These results
suggested that VEGF-A and COX-2 mRNAs, which are exported to
the cytoplasm by HuR, have important roles in TEC motility
through Akt signalling.
HuR knockdown inhibits TEC tube formation
The involvement of HuR in TEC angiogenic properties was
investigated using a tube formation assay (Figure 6). Representa-
tive data are shown (Figure 6A and B). A quantitative analysis of
junction numbers in tubes is also shown (Figure 6C). The ability
to form capillary-like structures was impaired by HuR knockdown
in oral carcinoma and melanoma ECs.
The ability to form capillaries in TECs was restored partially in
the presence of VEGF or PGE2, suggesting that HuR is important
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sfor TEC tube formation. Hu antigen R knockdown suppresses
angiogenic phenotypes of TECs and may cause an anti-angiogenic
effect.
DISCUSSION
This study provided several results including the following: (1)
VEGF-A and COX-2 mRNA were upregulated in mouse TECs
isolated from tumour xenografts; (2) HuR was highly expressed in
the cytoplasm of cultured mouse TECs and human TECs in vivo;
(3) HuR bound to VEGF-A and COX-2 mRNAs and stabilised them
in the TEC cytoplasm; (4) HuR knockdown led to the inhibition of
cell survival, random motility, and tube formation in TECs; and
(5) HuR knockdown suppressed Akt phosphorylation and TECs
tube formation.
There are several reports about the relationship between HuR
and ARE-mRNA (Brennan and Steitz, 2001) or the correlation
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sbetween cytoplasmic HuR expression and malignancy in tumour
cells (Lopez de Silanes et al, 2003, 2005; Denkert et al, 2004;
Erkinheimo et al, 2005; Heinonen et al, 2005; Cho et al, 2007a,b;
Niesporek et al, 2008; Hasegawa et al, 2009). However, there are
few reports about HuR and ARE-mRNA in ECs (Tschernatsch et al,
2006; Annabi et al, 2009), and no reports on the mechanism
of accumulated VEGF-A or COX-2 mRNA expression in TECs. We
have previously reported abnormalities of TECs (Hida et al, 2004;
Hida and Klagsbrun, 2005; Ohga et al, 2009); they grow faster and
migrate better than NECs (Matsuda et al, 2010). In our isolated
mouse TECs, several genes, such as VEGFR-2, CD13 (Pasqualini
et al, 2000), and Dkk-3 (Untergasser et al, 2008; Fong et al, 2009),
which are reported to be the upregulated genes in TECs, were
indeed upregulated. Furthermore, TECs are cytogenetically abnor-
mal (Hida et al, 2004; Akino et al, 2009). They have a lower serum
requirement, and although more responsive to angiogenic factors,
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Figure 5 TEC survival, cell motility, and Akt phosphorylation were inhibited by HuR knockdown. TEC survival was analysed under low serum condition by
counting the number of live cells at 72h after siRNA transfection (A). TEC survival rate under serum-starved conditions decreased significantly by HuR
knockdown (*Po0.05 vs skin EC). Random motility of TECs was analysed using Boyden chamber migration assay (B). After siRNA transfection for 48h,
endothelial basal media without growth factors (0.5% serum) was added to both the upper and lower wells to analyse random cell motility, and migrating
cells moving towards the lower well were counted 6h later. Cell motility was inhibited significantly by HuR knockdown (*Po0.05 vs skin EC). Cell motility
was restored when TECs were treated with VEGF (10ngml
–1) or PGE2 (10nM). The levels of phosphorylated Akt (P-Akt) were determined by western
blotting using an anti-P-Akt antibody (C, top lane). The membrane was stripped and reincubated with anti-total Akt (T-Akt) antibody (C, middle lane) and
b-actin antibody (C, bottom lane) to detect the quantity of T-Akt and b-actin protein. Levels of P-Akt were normalised to T-Akt using densitometry. The
graph shows the relative ratio of P-Akt/T-Akt analysed using densitometry. HuR knockdown inhibited Akt phosphorylation.
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sthey are more resistant to anti-cancer drug treatment, such as
5-fluorouracil (Hida et al, 2008). In this study, two angiogenic
growth factors, VEGF-A and COX-2, were highly expressed in
TECs compared with those in NECs, supporting previous findings
about increased survival activity of TECs.
Since VEGF-A and COX-2 are ARE-mRNAs, we focused on the
role of HuR in TECs. Several ARE-mRNAs, which are transcripts of
oncogenes or growth factor genes, are upregulated in malignant
cells. One of the accumulation mechanisms of these mRNAs is
their stabilisation by HuR (Brennan and Steitz, 2001). In this study,
we showed that HuR existed not only in the nucleus but also in the
cytoplasm of TECs, and this result suggests that HuR was exported
to the cytoplasm as reported in tumour cells. Furthermore,
we showed that HuR knockdown caused decreased VEGF-A and
COX-2 mRNA levels and shortened the half-life of these mRNAs,
and their protein levels. In addition, we demonstrated that HuR
binds to VEGF-A and COX-2 mRNAs by RIP assay. These results
suggest that HuR contributes to the stabilisation of VEGF-A and
COX-2 mRNAs in TEC cytoplasm.
In our data of western blotting, we used b-actin as an internal
control. It was shown that b-actin expression level was changed by
HuR knockdown in Hela cells (Dormoy-Raclet et al, 2007).
However, there are also several reports showing that the
expression of b-actin was not changed even when HuR level was
changed in other types of tumour cells (Abdelmohsen et al, 2008;
Ghosh et al,2 0 0 9 ;H a s e g a w aet al,2 0 0 9 ) .S i n c eb-actin was not
changed in our case of TECs either, we used it as an internal control
for western blotting, It was considered that the interaction between
b-actin and HuR may be different depending on the cell type.
Hu antigen R knockdown inhibited survival, random motility,
and tube formation in TECs and also inhibited Akt phosphoryla-
tion, suggesting that it has key roles in the TEC angiogenic
phenotype by upregulating mRNAs of the angiogenic factors
VEGF-A and COX-2. Since HuR reportedly stabilises not only
VEGF-A and COX-2 mRNAs but also other ARE-mRNAs, it is
possible that downregulation of survival, random motility, and
tube formation in TECs occurred due to downregulation of other
ARE-mRNAs. However, adding VEGF and PGE2 restored the
angiogenic properties of TECs such as cell survival, migration,
and tube formation with recovery of Akt phosphorylation, even
with HuR knockdown. Hu antigen R-mediated VEGF-A and
COX-2 mRNA upregulation has an important role in tumour
angiogenesis. The VEGFR-1 and VEGFR-2 mRNA expression levels
and Akt phosphorylation levels were higher in TECs than in NECs
(Ohga et al, 2009). This suggests that there might be an autocrine
pathway for cell survival and migration in TECs due to HuR
translocation into the TEC cytoplasm. This result was not found
in NECs.
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Figure 6 Tube formation of TECs was inhibited by HuR knockdown. TECs were seeded onto Matrigel in basal medium, and tube formation was
observed after 12h incubation (A and B) and the number of junctions counted (C and D)( * Po0.01 vs HuR SiRNA. Tube formation was significantly
inhibited by HuR siRNA both in oral carcinoma and melanoma ECs. When cells were treated with VEGF (10ngml
–1) or PGE2 (10nM), the number of
junctions was restored. Representative figures are shown (black bar: 100mm).
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proliferative and resistant to serum starvation with over-
expressed VEGF-D and activated Akt phosphorylation, suggesting
that TECs are stimulated in an autocrine manner (Bussolati
et al, 2003).
In conclusion, we demonstrated for the first time that VEGF-A
and COX-2 mRNAs are stabilised in TECs. Hu antigen R
knockdown changed the features of TECs required for tumour
angiogenesis. These results suggest that HuR may contribute
to ARE-mRNA accumulation specifically in TECs and may
keep an angiogenic switch on in TECs themselves. Hu antigen R
knockdown may have potential as an effective therapeutic
approach.
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